Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

VHT is positioned as a lower-cost, diversified healthcare ETF versus the more concentrated biotech-focused FBT: expense ratio 0.09% vs 0.55% (a ~46 bps annual cost advantage). Over the last year, FBT returned 51.6% vs VHT’s 25.2%, but FBT also shows higher risk with a larger 5-year max drawdown (-29.9% vs -17.7%). The article highlights VHT’s 411 holdings across major pharma (e.g., Eli Lilly 14.19%, J&J 8.89%) versus FBT’s 30 biotech names (top holdings around 3.5% each), implying broader downside absorption in VHT and sharper single-name beta in FBT.

Analysis

The real signal here is not "healthcare up or down"; it is a preference for quality, liquidity, and lower event risk inside the sector. FBT’s recent edge is the kind of outperformance that usually comes from a narrow window of M&A and clinical beta, which can persist for a few quarters but is fragile once deal premiums compress or one or two trial disappointments hit. VHT is the more durable allocator product because the fee drag is trivial and the underlying basket is dominated by cash-generative large caps that can absorb single-name shocks.

Second-order, if capital rotates from concentrated biotech into broad healthcare, the marginal winners are the mega-cap pharma and diversified healthcare franchises inside VHT, not the smaller names that often carry the index. That means LLY, ABBV, and JNJ are the cleaner beneficiaries of passive and quasi-passive healthcare inflows, while names like ONC, VCYT, and NEO remain highly dependent on external catalysts and financing conditions. The drawdown profile matters: FBT can keep outperforming in a risk-on tape, but its realized volatility is the hidden tax that becomes visible as soon as the market stops paying up for biotech optionality.

Contrarian view: the market may be over-crediting the durability of the current biotech M&A cycle. If rates stay elevated and acquirers become more selective, takeover probabilities fall and FBT’s concentration works against you because there is no diversification buffer. Falsifier is simple: if biotech deal activity and favorable FDA surprises stay elevated into the next 1-2 quarters, relative performance can keep running and the pair trade loses timing edge.

Key Decisions for Investors

• Long VHT / short FBT as a 3-6 month relative-value pair; target 5-10% spread convergence toward broader healthcare leadership, and cut if FBT outperforms VHT by another 5% on sustained M&A/FDA momentum.
• For fresh healthcare allocations, favor VHT over FBT over the next 1-3 months: lower fee drag, lower drawdown risk, and cleaner exposure to LLY/ABBV/JNJ rather than single-name biotech gaps.
• Use VHT as the defensive healthcare sleeve in multi-asset portfolios and pair it against higher-beta cyclical exposures; it should outperform on a risk-adjusted basis if equity volatility rises or biotech deal flow cools.
• If you want biotech exposure, wait for a pullback or a catalyst reset before adding FBT; do not chase after a strong 12-month run unless the next FDA/earnings cycle confirms the momentum.
• Watch for secondary offerings, trial readouts, or M&A slowdown in smaller biotech holdings like ONC, VCYT, and NEO; those are the earliest warning signs that should reinforce a short-FBT / long-VHT stance.